Equity Details
Price & Market Data
Price: $2.28
Daily Change: -$0.11 / 4.82%
Daily Range: $2.27 - $2.43
Market Cap: $78,994,856
Daily Volume: 679,208
Performance Metrics
1 Week: 0.44%
1 Month: 37.35%
3 Months: -5.00%
6 Months: 14.00%
1 Year: 47.10%
YTD: -34.10%
About Annovis Bio, Inc. (ANVS)
Financial insights into Annovis Bio, Inc. (ANVS). Current price: 2.28, daily change: -$0.11 / 4.82%. Market cap: 78,994,856. Performance metrics across all timeframes are updated.
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.